October 23, 2015 / 11:20 AM / 2 years ago

Amgen's virus-based cancer drug wins European green light

1 Min Read

LONDON, Oct 23 (Reuters) - An experimental Amgen drug based on a tumour-killing virus was given a green light by European regulators on Friday, paving the way for the novel treatment's approval within a couple of months.

The decision is a further milestone for a technology that has long fascinated scientists but has previously proved difficult to harness.

The European Medicines Agency said its experts had recommended approval of talimogene laherparepvec or "T-Vec" for treating melanoma, making it another option among several new drugs for fighting for the most deadly form of skin cancer. (Reporting by Ben Hirschler; editing by Jason Neely)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below